Research programme: protease inhibitors - Medivir/Paradigm Therapeutics
Alternative Names: Protease inhibitor research programme - Medivir/Paradigm TherapeuticsLatest Information Update: 12 Feb 2008
At a glance
- Originator Medivir AB; Paradigm Therapeutics
- Developer Medivir AB; Takeda Cambridge
- Class Small molecules
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 12 Feb 2008 Discontinued - Preclinical for Undefined indication in United Kingdom (unspecified route)
- 27 Apr 2007 No development reported - Preclinical for Undefined indication in United Kingdom (unspecified route)